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Abstract: A post-antibiotic world is fast becoming a reality, given the rapid emergence of pathogens
that are resistant to current drugs. Therefore, there is an urgent need to discover new classes of
potent antimicrobial agents with novel modes of action. Cannabis sativa is an herbaceous plant that
has been used for millennia for medicinal and recreational purposes. Its bioactivity is largely due to
a class of compounds known as cannabinoids. Recently, these natural products and their analogs
have been screened for their antimicrobial properties, in the quest to discover new anti-infective
agents. This paper seeks to review the research to date on cannabinoids in this context, including an
analysis of structure–activity relationships. It is hoped that it will stimulate further interest in this
important issue.
Keywords: antibiotics; antimicrobial resistance; MRSA; Cannabis sativa; cannabinoids; structure–
activity relationships
1. Introduction
The discovery of antibiotics is undoubtedly one of the most important scientific achievements in
modern medicine and has saved millions of lives since their discovery. However, their misuse has
resulted in the emergence of antibacterial resistance (AMR), which is a significant threat to global
human health. It is estimated that global deaths could reach 10 million per year by 2050 with a
cumulative cost to global economic output of US$100 trillion [1]. The World Health Organization has
highlighted that AMR is one of the three greatest threats to healthcare systems globally [2]. For example,
immuno-compromised patients such as organ transplant recipients and those who are undergoing
chemotherapy treatment are particularly vulnerable and depend on the efficacy of antibiotics to fight
off infection [3,4]. The spread of multidrug-resistant (MDR) bacteria therefore threaten these significant
advancements in medical care. Despite this, only four new classes of antibiotics have reached the clinic
in the past four decades [5]. The development of new classes of anti-infective agents with novel modes
of action is therefore essential to address the growing threat of AMR.
Cannabis sativa is an herbaceous plant that belongs to the family Cannabinaceae [6]. It has been used
by humans for over 5,000 years for medicinal and recreational uses, firstly in Central and Northeast Asia
and subsequently spreading worldwide [7]. Cannabis, or marijuana, is undoubtedly one of the most
widely used illicit drugs [8]. It has a complex chemical composition that includes cannabinoids [9], which
are a group of secondary metabolites, several of which are responsible for the psychotropic effects [10,11].
Metabolic fingerprinting of C. sativa unveiled more than 480 compounds, including many terpenes and
approximately 180 cannabinoids [12]. Their biosynthesis involves the alkylation of olivetolic acid with
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geranyl diphosphate, which is catalyzed via geranyl transferase [13]. This reaction leads to the formation
of cannabigerolic acid (CBGA, Figure 1A), which is a precursor molecule for numerous other cannabinoids,
such as ∆9-tetrahydrocannbinol (∆9-THC), cannabidiol (CBD), cannabigerol (CBG), cannabinol (CBN)
and cannabichromene (CBC) (see Figure 1B–F) [14,15].
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Although the medicinal use of abis i to the 13th century, it was only
popularized in the 19th century when it was found to have anticonvulsive, analgesic, antianxiety
and antiemetic effects [21]. Over the past decade, advocates of medicinal cannabis have highlighted
its pote tial for treating a variety of con itions, including cancer [22]. This has sparked a ra ge of
reactions, from reluctance and caution [23] to excitement [24]. The reluctance stems from the adverse
effects of cannabis, which limit its widespread therapeutic use. Cannabis use has been known to cause
psychological effects for at least 4,000 years [25], including symptoms such as euphoria, intensification
of sensory perceptions and impaired motor skills in healthy individuals [26]. Most commonly, it has
well-documented deleterious effects on neurocognitive functioning in humans [27]. It has also been
linked to deficits in working and episodic memory [28], executive functions [29], anhedonia and
anxiety [30]. A recent report by the WHO also suggested an association between myocardial infarction
or stroke with heavy cannabis use [31]. The adverse effects on the cardiovascular system is most
likely caused by CB1 receptor activation by ∆9-THC, while CBD seems to have beneficial effects [32].
Moreover, some medical professionals have concerns about prescribing medicinal cannabis (where it is
legalized) due to its potential addictive properties. However, it should be acknowledged that there are
disparities and contradictions in findings between studies. Regardless, healthcare practitioners should
be aware of these adverse effects and inform their patients before prescription. Recently, evidence
surrounding the use of cannabinoids on treatment-resistant refractory epilepsy has increased [33–35].
There are also strong indications that cannabinoids are effective agents for the treatment of chronic
pain, nausea post-chemotherapy and appetite stimulation [36–40].
2. Antibacterial Effects of C. sativa Extracts
The first reports detailing the antibacterial activity of cannabinoids date back to the 1950s [41,42].
These experiments were conducted before the phytochemistry of cannabis was well characterized,
which means that the bactericidal effect of C. sativa could not be directly attributed to a specific
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constituent. This was achieved in 1976, where it was found that ∆9-THC and CBD are bacteriostatic as
well as bactericidal against a panel of Gram-positive pathogens (see below) [43]. There has also been
great interest in the antibacterial properties of the essential oils and various extracts from C. sativa, such
as those derived from petroleum ether, methanol and hot water. Various methods for isolating C. sativa
extracts have also been applied. Traditional techniques include cold-pressing and solvent extraction,
however higher yielding technologies which generate superior products are now emerging [44].
Pressurized liquid extraction circumvents the need for filtration, whereas ultrasonic-assisted extraction
(UAE) methods use less solvent and have short processing times, with higher yields and equivalent
quality. “Green” methods include microwave-assisted extraction and supercritical fluid extraction,
however up-scaling is challenging for the latter process [44].
Novak and co-workers evaluated the essential oils of five different cultivars of C. sativa against
a large panel of Gram-positive and Gram-negative pathogens. The most abundant compounds in
each oil sample were α-pinene, myrcene, trans-β-ocimene, α-terpinolene, trans-caryophyllene and
α-humulene. The antimicrobial activity was in general poor, with only modest activity against
Acinetobacter calcoaceticus and Brevibacterium linens. No ∆9-THC and very low levels of CBD and CBN
were detected in all the essential oils, which suggests a role of these compounds in the antimicrobial
activity of C. sativa [45]. A later study evaluated the oil of the seeds from the whole plant, extracted
by petroleum ether and methanol. It was found (via the cup–plate agar diffusion method) that each
extract exhibited an antimicrobial effect against Gram-positive pathogens. This is consistent with the
study by Van Klingeren et al. [43], although the cannabinoid content of the plant specimen was not
characterized. No significant antifungal activity was observed. Intriguingly, minor activity against
Gram-negative bacteria was also reported, albeit a modest effect (note that the petroleum ether extract
was inactive against Pseudomonas aeruginosa) [46]. Hot water and ethanol leaf extracts have also been
shown to possess an inhibitory effect against Gram-negative pathogens [6].
Lone and Lone investigated and compared the protein yield and antimicrobial and antioxidant
effects of C. sativa following both aqueous and acetone extraction [47]. From 500 g samples, protein
extraction from aqueous methodologies yielded 4.8 g of crude extract and 3.2 g from acetone.
When compared with the aqueous extract, the acetone extract displayed fractionally superior bactericidal
properties. A concentration-dependent response was observed against all strains, with V. cholera being
marginally the most responsive bacteria, closely followed by P. aeruginosa. The fungal response was
slightly more pronounced in C. albicans compared to C. neoforms. Additionally, this study found that
C. sativa has antioxidant properties, thus widening its potential for clinical use.
Sarmadyan et al. investigated the antimicrobial properties of “Hashish” against common
hospital-associated bacterial strains [48]. Disk diffusion experiments found that cannabis extract
exerted the greatest antimicrobial effects on S. aureus 25923, with an inhibition zone of 14 mm, followed
by MRSA, E. coli and K. pneumoniae with values of 12, 10 and 7 mm, respectively. No activity was
observed in P. aeruginosa or A. baumannii. This trend regarding spectrum of activity is consistent with
the findings of Vu et al., whereby extracts from Vietnamese derived C. sativa plants were found to
possess modest antimicrobial activity against Gram-positive bacteria, with Gram-negative bacteria
being less susceptible [49]. Similarly, Lelario and co-workers also observed that the major components
of C. sativa extracts displayed moderate activity only against Gram-positive pathogens [50].
Hemp seed oil–water emulsions have also been under investigation for pharmaceutical and
cosmetic applications, due to their low toxicity and biodegradability. The antimicrobial activity of
two emulsions, consisting of both unrefined and refined oil, was determined. Overall, the bactericidal
effect against Gram-positive pathogens was modest and less so for Gram-negative bacteria (virtually
zero activity against Escherichia coli CCM 3954 was observed). The refined oil was also less potent than
the unrefined oil. This could be due to the higher content of α-linolenic acid in the latter, or more
likely the fact that ∆9-THC is removed during the refinement process [51]. Ethanol extracts of C. sativa
leaves have also been tested against both clinical samples and nonclinical MRSA isolates, via the
disc diffusion method. For the clinical isolates, the inhibition zone diameter ranged 9–15 mm, which
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was somewhat less than vancomycin (13–24 mm). However, 1:1 combination with other medicinal
plant extracts such as Psidium guajava and Thuja orientalis demonstrated a synergistic effect, whereby
inhibition zone diameters ranged 25–30 mm in most cases. This synergy may be due to the presence
of quercetin, gallic acid and flavonoids such as catechin, which were detected in the leaf extracts;
however, no cannabinoids were detected [52]. Interestingly, Frassinetti and co-workers observed
inhibitory activity of C. sativa seed extracts on S. aureus biofilm formation, which indicates that these
extracts could have enormous potential as preservatives in both the food and cosmetics industries [53].
Similarly, Stahl et al. found that cannabinoids are more effective in reducing the bacterial colony count
in dental plaque when compared with commercial toothpastes such as Oral B and Colgate, which
suggests that C. sativa-derived compounds could be used for oral care applications [54].
Investigation is also underway into the biological activity of commercially viable ∆9-THC-free
essential oil of C. sativa, which could have medicinal, cosmetic, veterinary, agronomic or food
applications. The oil was evaluated against several S. aureus strains and exhibited both a moderate
antibacterial effect and antibiofilm activity, which was partly attributable to the flavanone naringenin.
Antimicrobial activity was also observed against Helicobacter pylori (a Gram-negative organism) but no
anti-fungal activity was observed. This study demonstrates that C. sativa is a rich source of biologically
active compounds and that its antimicrobial properties are not solely attributable to cannabinoids [55].
Hemp seed hexane extracts have also been evaluated. The resultant oil was found to inactivate the
growth of acne-causing Propionibacterium acnes as well as possess an anti-inflammatory effect [56].
Recently, Iseppi and co-workers conducted an extensive phytochemical characterization of
17 hemp essential oils from different varieties. Seventy-one compounds were identified, with the
terpenes β-myrcene, α-pinene, α-terpinolene, β-pinene, trans-ocimene and limonene being the
most abundant. CBDV, CBC and CBD were also detected, but below 0.05% of the percentage
area in each chromatogram. The minimum inhibitory concentration (MIC) values of each oil were
determined against a panel of Gram-positive pathogens and were found to have moderate to good
antimicrobial activity. To determine the source of the observed antibacterial effect, the afore-mentioned
terpenes and CBD were also evaluated. In general, good to moderate activity was observed against
Listeria monocytogenes and Enterococcus isolates, but slightly less so for Staphylococcus and Bacillus
isolates. Therefore, the antimicrobial effect is likely to be due to synergism between several compounds
that are present in the essential oils [57].
An interesting application for C. sativa-derived compounds is to use them for water filtration
and purification purposes. Nadir et al. immobilized a mixture of cannabinoids and terpenes onto
a polyethersulfone hybrid membrane. Bacterial decline was observed for both Gram-positive and
Gram-negative pathogens. For example, an 88% decrease bacterial load for S. aureus was measured for
the hybrid membrane compared to 30% for the standard membrane. Similar results were reported for
several other species, including for Pseudomonas aeruginosa and Escherichia coli. This study represents
a cost-effective solution for water filtration and antibacterial purification [58]. All these examples
highlight the great potential of C. sativa and its antimicrobial properties for applications in food,
agriculture and drug discovery.
3. Structure–Activity Relationships of Cannabinoids
Although it has long been known that marijuana has antibacterial properties, its potential to
address the major global crisis of antibiotic resistance is largely untapped. There have been a few
studies, however, which are outlined below. When reading this section, please refer to Figure 2 and the
Supplementary Materials, which contain each numbered structure that is indicated in bold text.
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bactericid l effect was attenuated in the presence of horse s rum, possibly due to the ca nabinoids
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active than their analogous cannabichromene. This class of cannabinoid does not induce intoxicating
effects, which improves their therapeutic potential.
Appendino et al. investigated the antibacterial activity of five ajor cannabinoids and their analogs
against a range of MDR S. aureus isolates [60]. It was found that cannabidiolic acid (CBDA) possesses
good antimicrobial activity (MIC = 2 µg/mL, 8), which was further improved with omission of the
carboxylate moiety (9). This has recently been verified by Martinenghi and co-workers, who observed
that against several Gram-positive pathogens, CBD had MIC values in range of 1–2 µg/mL, compared
with CBDA (2–4 µg/mL) [61]. The methyl and phenethyl esters of CBDA were inactive (13, 14), which
could be caused by the added hydrophobicity and/or steric bulk. Acetylation or methylation of
the hydroxyl groups (10–12) was also detrimental for activity and indicates the importance of the
resorcinol moiety. The MIC for cannabichromene (15) was 1–2 µg/mL, which is consistent with the
findings of Turner et al. [59]. CBGA (16) possessed moderate activity, which was again improved with
removal of the carboxylate (CBG, 17). Acetylation (18) and methylation (19, 20) of the hydroxyls was
again detrimental for activity, as was esterification of CBGA (21, 22). ∆9-THC acid (23) possessed
only a moderate bactericidal effect compared to ∆9-THC and CBN (24, 25). Interestingly, swapping
the hydroxyl at position 1 and the n-pentyl group at position 3 in both CBD and CBG (26, 27) did
not significantly affect activity. Di-hydroxylation of the prenyl tail in CBG (28) attenuated potency;
prenylation at position 2 abolished activity. Resorcinol was also evaluated with and without an n-pentyl
group (30, 31); although the overall antimicrobial effect was poor, it still demonstrated the importance
of the hydrocarbon chain.
Recently, Feldman et al. evaluated the endocannabinoids anandamide and arachidonyl serine
(32, 33) [62]. Although they exhibited poor bactericidal activity against planktonic MRSA isolates, they
strongly inhibited biofilm formation, with a reduction of metabolic activity of pre-formed biofilms.
Furthermore, cell aggregation, hydrophobicity, membrane potential and spreading ability, which are
biofilm-associated virulence determinants, were altered. Therefore, these agents have potential as a
treatment for recalcitrant MRSA biofilm infections, potentially in combination with existing antibiotics
such as ampicillin and gentamicin [63]. This approach is effective, as it has been demonstrated that
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CBD (34) potentiates the antimicrobial effect of the peptide drug bacitracin against Staphylococcus
species, L. monocytogenes and E. faecalis [64].
Farha and co-workers evaluated several cannabinoid analogs against MRSA USA300 and E. coli [65].
Several common cannabinoids (35–43, 45, 47) demonstrated moderate to good activity; these results
mostly align with previous studies (vide supra). ∆9-Tetrahydrocannabivarin (44) and related analogs
(46, 48, 49), which bear a common n-propyl chain at position 3, experienced up to a four-fold increase
in MIC values, thus further highlighting the importance of the n-pentyl chain, which could play a
role in membrane insertion. Carboxylation (50) and hydroxylation (51) at position 11 of ∆9-THC
resulted in a loss of activity which indicates that lipophilicity may be important in the prenyl tail.
Polycyclic cannabicyclol had low activity (52). CBG showed promising levels of efficacy in a murine
systemic infection model of MRSA whereby the bacterial burden in the spleen was reduced by a factor
of 2.8 log10 in CFU. None of these analogs displayed a bactericidal effect against E. coli however, with
consistent MIC values of >128 µg/mL recorded. Interestingly, CBG was found to be effective against
Gram-negative organisms in combination with polymyxin B or the less nephrotoxic polymyxin B
nonapeptide. It is proposed that polymyxins permeabilize the outer membrane of Gram-negative
pathogens to enable CBG to act on the inner membrane. Similarly, Kosgodage et al. found that
CBD can act as a sensitizing agent in combination with various antibiotics [66]. For Gram-negative
pathogens, CBD strongly inhibited the release of membrane vesicles, which play a role in inter-bacterial
communication and the transfer of cargo molecules. When E. coli VCS257 was treated with CBD
in combination with erythromycin, vancomycin, rifampicin, kanamycin or colistin, an enhanced
antimicrobial effect was observed. These results are significant as they highlight the potential
of cannabinoids as potentiators to improve the efficacy and broad-spectrum activity of existing
antibiotic drugs.
4. Conclusions
C. sativa is a plant with untapped potential. It has an extensive metabolic profile and its medicinal
properties should not be overlooked or overshadowed by its overuse as a recreational drug. Current antibiotic
drugs have limited efficacy against MDR bacteria and their usage can be limited due to their toxicity
for prolonged treatments; therefore, the discovery of an antimicrobial therapy of plant origin will no
doubt be a great advancement in the field of anti-infectives [6]. Several cannabinoids have been
found to have potent antimicrobial activity against Gram-positive pathogens such as MRSA isolates.
Endocannabinoids have also been shown to be effective in eradicating biofilms. Combination therapy
with bactericidal agents that possess different modes of action such as polymyxin B have shown
synergism and broad-spectrum activity. There is also evidence that other compounds found in
C. sativa such as terpenes have promising antimicrobial activity, which warrants further investigation.
As bacteria are rapidly developing resistance against existing drugs, cannabinoids present a novel and
exciting opportunity as a potential new source of antibiotics.
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